Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms- |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 19 Nov 2020 | |
COVID-19 | Phase 3 | Brazil | 19 Nov 2020 | |
COVID-19 | Phase 3 | Canada | 19 Nov 2020 | |
COVID-19 | Phase 3 | United Kingdom | 19 Nov 2020 |
Phase 1/2 | 128 | (MT-2766 High Dose (3.75 µg)) | fglxzzclfa = jsgryycvkb irtdajfqeb (sfhamfqhjj, fkfzcwtpkh - qjblcmfoxk) View more | - | 01 May 2023 | ||
Placebo (Placebo) | fglxzzclfa = fjsxtxxtik irtdajfqeb (sfhamfqhjj, dfiudfqmvp - wsvnfouynm) View more |